{"id":56090,"date":"2026-02-02T22:48:31","date_gmt":"2026-02-02T14:48:31","guid":{"rendered":"https:\/\/flcube.com\/?p=56090"},"modified":"2026-02-02T22:48:33","modified_gmt":"2026-02-02T14:48:33","slug":"zenshine-pharma-files-for-hong-kong-ipo-with-357m-valuation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56090","title":{"rendered":"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nanjing Zenshine Pharmaceuticals Co., Ltd.<\/strong> submitted its initial public offering (IPO) filing to the <strong>Main Board of the Hong Kong Stock Exchange<\/strong>. Founded in <strong>2018<\/strong>, the small\u2011molecule drug developer focuses on viral infectious diseases, oncology, and inflammatory diseases, with a post\u2011investment valuation of <strong>RMB\u202f2.482\u202fbillion (USD\u202f357\u202fmillion)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-ipo-details\">Company Profile &amp; IPO Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Nanjing Zenshine Pharmaceuticals Co., Ltd.<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2018<\/td><\/tr><tr><td><strong>IPO Venue<\/strong><\/td><td>Hong Kong Stock Exchange Main Board<\/td><\/tr><tr><td><strong>Valuation<\/strong><\/td><td>RMB\u202f2.482\u202fB (USD\u202f357\u202fM) post\u2011D++ round<\/td><\/tr><tr><td><strong>Latest Financing<\/strong><\/td><td>D++ round: RMB\u202f20\u202fM (USD\u202f2.9\u202fM) in January\u202f2026<\/td><\/tr><tr><td><strong>Focus Areas<\/strong><\/td><td>Viral infectious diseases, oncology, inflammatory diseases<\/td><\/tr><tr><td><strong>Core Product<\/strong><\/td><td>Sebaloxavir marboxil (influenza, approved July\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-overview\">Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Mechanism<\/th><th>Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Sebaloxavir marboxil<\/strong><\/td><td>Cap\u2011dependent endonuclease inhibitor<\/td><td>Influenza (adults)<\/td><td>Launched (July\u202f2025)<\/td><\/tr><tr><td><strong>ZX-8177<\/strong><\/td><td>ENPP1 inhibitor<\/td><td>Solid tumors<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>ZX-15002<\/strong><\/td><td>\u2014<\/td><td>Herpes simplex virus infections<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>ZX-12042B<\/strong><\/td><td>\u2014<\/td><td>HPV infections<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>ZX-14000<\/strong><\/td><td>STAT6 degrader<\/td><td>Autoimmune diseases<\/td><td>Preclinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Influenza Market:<\/strong> China influenza antiviral market valued at <strong>\u00a56\u202fbillion<\/strong> : (~US$850\u202fM) in 2025; sebaloxavir marboxil positioned as first\u2011in\u2011class cap\u2011dependent endonuclease inhibitor<\/li>\n\n\n\n<li><strong>Oncology &amp; Virology Pipeline:<\/strong> ZX-8177\u2019s ENPP1 inhibition targets tumor microenvironment; HPV and HSV programs address significant unmet needs in infectious diseases<\/li>\n\n\n\n<li><strong>IPO Timing:<\/strong> Filing capitalizes on strong biotech IPO window in Hong Kong; proceeds will fund Phase\u202fII\/III trials and commercialization scale\u2011up<\/li>\n\n\n\n<li><strong>Valuation Justification:<\/strong> $357\u202fM valuation reflects commercial validation via sebaloxavir launch and early\u2011stage pipeline potential<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>Roche, GSK, AstraZeneca<\/strong> in influenza; ZX\u20118177 targets <strong>Takeda, Bristol Myers<\/strong> in immuno\u2011oncology<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> IPO pricing expected <strong>Q2\u202f2026<\/strong>; secondary offering planned for 2027 to fund ZX\u20118177 IND\u2011enabling studies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IPO timelines, clinical development plans, and revenue projections for Zenshine Pharma. Actual results may differ due to market conditions, regulatory review, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26013001890_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26013001890_c.\"><\/object><a id=\"wp-block-file--media-c9f4cc08-ec92-4dcf-b576-2bafae1e3300\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26013001890_c.pdf\">sehk26013001890_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26013001890_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c9f4cc08-ec92-4dcf-b576-2bafae1e3300\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56092,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[72,1527],"class_list":["post-56090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-zenshine-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zenshine Pharma Files for Hong Kong IPO with $357M Valuation - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main Board of the Hong Kong Stock Exchange. Founded in 2018, the small\u2011molecule drug developer focuses on viral infectious diseases, oncology, and inflammatory diseases, with a post\u2011investment valuation of RMB\u202f2.482\u202fbillion (USD\u202f357\u202fmillion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56090\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation\" \/>\n<meta property=\"og:description\" content=\"Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main Board of the Hong Kong Stock Exchange. Founded in 2018, the small\u2011molecule drug developer focuses on viral infectious diseases, oncology, and inflammatory diseases, with a post\u2011investment valuation of RMB\u202f2.482\u202fbillion (USD\u202f357\u202fmillion).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56090\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T14:48:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T14:48:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0214.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation\",\"datePublished\":\"2026-02-02T14:48:31+00:00\",\"dateModified\":\"2026-02-02T14:48:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090\"},\"wordCount\":314,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0214.webp\",\"keywords\":[\"IPO\",\"Zenshine Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56090#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56090\",\"name\":\"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0214.webp\",\"datePublished\":\"2026-02-02T14:48:31+00:00\",\"dateModified\":\"2026-02-02T14:48:33+00:00\",\"description\":\"Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main Board of the Hong Kong Stock Exchange. Founded in 2018, the small\u2011molecule drug developer focuses on viral infectious diseases, oncology, and inflammatory diseases, with a post\u2011investment valuation of RMB\u202f2.482\u202fbillion (USD\u202f357\u202fmillion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56090\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0214.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0214.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56090#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main Board of the Hong Kong Stock Exchange. Founded in 2018, the small\u2011molecule drug developer focuses on viral infectious diseases, oncology, and inflammatory diseases, with a post\u2011investment valuation of RMB\u202f2.482\u202fbillion (USD\u202f357\u202fmillion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56090","og_locale":"en_US","og_type":"article","og_title":"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation","og_description":"Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main Board of the Hong Kong Stock Exchange. Founded in 2018, the small\u2011molecule drug developer focuses on viral infectious diseases, oncology, and inflammatory diseases, with a post\u2011investment valuation of RMB\u202f2.482\u202fbillion (USD\u202f357\u202fmillion).","og_url":"https:\/\/flcube.com\/?p=56090","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-02T14:48:31+00:00","article_modified_time":"2026-02-02T14:48:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0214.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56090#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56090"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation","datePublished":"2026-02-02T14:48:31+00:00","dateModified":"2026-02-02T14:48:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56090"},"wordCount":314,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56090#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0214.webp","keywords":["IPO","Zenshine Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56090#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56090","url":"https:\/\/flcube.com\/?p=56090","name":"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56090#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56090#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0214.webp","datePublished":"2026-02-02T14:48:31+00:00","dateModified":"2026-02-02T14:48:33+00:00","description":"Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main Board of the Hong Kong Stock Exchange. Founded in 2018, the small\u2011molecule drug developer focuses on viral infectious diseases, oncology, and inflammatory diseases, with a post\u2011investment valuation of RMB\u202f2.482\u202fbillion (USD\u202f357\u202fmillion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56090#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56090"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56090#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0214.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0214.webp","width":1080,"height":608,"caption":"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56090#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zenshine Pharma Files for Hong Kong IPO with $357M Valuation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0214.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56090"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56090\/revisions"}],"predecessor-version":[{"id":56093,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56090\/revisions\/56093"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56092"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}